2954-4122

S2954-41222024000400146

10.24875/anc.m24000019

República Dominicana

México

EE.UU

00 12 2024

29 4 146 160

2014 S6

S415

2020 20

1047-64

2023 25

1-13

2017 3

17013

2021 20

559-72

2020 16

97-107

2011 26

1042-8

2021 11

177-86

2015 30

114-20

2018 162

17-36

2022 12

1073-82

2016 51

1-11

2023 130

793-820

2020 19

591-600

2021 12

705407

2022 387

421-32

2022 387

408-20

2021 58

3119-40

2020 9

2565

2023 38

386-98

2017 298

236-45

2017 8

508-19

2020 13

2021 16

2014 29

470-8

2018 18

2020 77

427-34

2021 11

S183-8

2023 38

1197-208

2015 82

495-503

2022 12

557-70

2013 2013

683920

2018

Identification of Novel Biologically Active DJ-1 Small Molecule Modulators with Activity in Cellular and in vivo Models of Oxidative Stress Relevant to Parkinson's Disease [presentation] 2016

2016 17

1585

2014 9

1998 150

60-8

2019 129

4539-49

2023 2

kvad001

2017 7

589-601

2011 31

157-63

2023 15

abp9352

2020 77

309-17

2018 27

2344-56

2021 64

15091-110

2013 22

31-7

2010 1

1-31

2019 124

81-92

2016 6

321

2019 150

104538

2020 28

607-27

Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD 2004 62

330-2

Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease 2007 69

1480-90

2023 257

115511

2021 14 10 10

926-39

2014 20

5507-9

2021 28

430-7

2016 11

2021 11

2021 70

S683-714

2021 272

119252

1983 64

261-9

2020 21

5982

2007 8

622-32

2021 16

2019 15

631-51

2020 11

1356

2019 9

5-16

2020 172

591-8

2018 8

16165

2019 9

7567

2018 33

684-96

2013 125

795-813

2016 113

E4688-97

2022 143

55-73

2017 59

156-70

2022 12

477-93

2019 132

104582

2014 69

134-43

2013 17

393-9

2016 5

283-91

2018 1415

47-56

2023 89

101979

2020 180

114187

2022 37

451-62

Parkinson Study Group STEADY-PD III Investigators. Isradipine versus placebo in early Parkinson disease 2020 172

591-8

2017 155

96-119

2020 127

181-7

2017 7

1398

2020 15

74-81

2022 22

657-73

2023 10

2021 374

1087-92

2019 99

1877-2013

2021 67

103380

2017 3

2022 12

2015 138

2687-700

2013 8

100

2018 15

193

101

2018 10

102

2021 28 2 2

82-9

103

2020 40 7 7

1155-64

104

2008 13 2 2

187-97

105

2020 10 11 11

1-10

106

2022 13

1-11

107

2018 8

15953

108

2016 23

1873-85

109

2019 13

1011-22

110

2023 9

111

2016 8

368ra174

112

2015 35

16463-78

113

2019 13

421

114

2016 4

23-33

115

2013 3

13-7

116

2019 20

728

117

2022 37

853-7

118

2022 18 9 9

2150-60

119

2020 12 6 6

1-12

120

2010 11

1-10

121

2010 70 1 1

288-98

122

2014 9 3 3

380-7

123

2022 18 3 3

559-75